5.190USDMkt Cap: 15.98M USDP/E: —Last update: 2026-05-22
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K …
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap15.98M USD
Enterprise Value12.52M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-13.24M USD
Revenue/Share—
Last Price5.190 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.32
PEG—
EV/EBITDA-1.04
EV/Revenue—
P/S—
P/B7.21
EPS (TTM)-5.59
EPS (Forward)-3.91
52W Range
5.00021% of range5.886
52W High5.886 USD
52W Low5.000 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-483.34%
ROA-305.95%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.60M USD
CapEx (TTM)5.10K USD
FCF Margin—
FCF Yield-39.46%
Net Debt-2.31M USD
Net Debt/EBITDA0.19
Balance Sheet
Debt/Equity—
Current Ratio2.68
Quick Ratio2.17
Book Value/Sh0.7170 USD
Cash/Share0.8050 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateAug 20, 2024
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)27.67 USD
Target Range13.00 USD – 45.00 USD
# Analysts3
Ownership
Shares Out.3.08M
Float2.38M
Insiders18.24%
Institutions5.97%
Short Interest
Short Ratio1.1d
Short % Float2.07%
Short % Out.1.77%
Shares Short54.35K
Short (prev mo.)29.41K
Technical
SMA 505.598 (-7.3%)
SMA 2009.228 (-43.8%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)101.40K
Avg Vol (10d)53.42K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—